gearing

NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimer’s Disease Treatment.

Summary: Progress in Neurodegenerative Research:  NKGen’s Phase 1/2a Clinical Trial for SNK01 on Track for End-of-Year Initiation SANTA ANA, Calif., Oct. 24, 2023 (Plato / Amplifi) -- Today, NKGen Biotech Inc. (Nasdaq: NKGN), a trailblazer in the field of autologous, allogeneic, and CAR-NK natural killer cell therapeutics, proudly announced the progression of its SNK01 program targeting Alzheimer’s Disease (AD), backed by the green light from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application. NKGen is gearing up to initiate its Phase 1/2a clinical trial

Digital Assets

If you ask most people in crypto what a digital asset is they usually reply that it covers everything in crypto. For over a year major exchanges and projects have been asking regulators the same question and are repeatedly frustrated by their inability to answer clearly. The reason is that the term ‘digital asset’ is one you’re likely to hear or read about frequently in the coming months. According to well-placed sources within financial journalism, regulators and lobbyists backed by legacy financial institutions are gearing up to label every cryptocurrency